Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN S CROSS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1336146927
CMS profile
106035
Location
AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,947.12

204 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,349.47 197
Travel and Lodging $1,476.77 5
Education $120.88 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN S CROSS

NPI 1336146927 · CMS profile ID 106035

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336146927?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN S CROSS, NPI 1336146927, CMS profile ID 106035. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336146927?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JONATHAN S CROSS, NPI 1336146927, CMS profile ID 106035. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336146927?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JONATHAN S CROSS, NPI 1336146927, CMS profile ID 106035, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1336146927?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

204 matching records · $6,947.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 204 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 204.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARGENX US, INC. $28.7510/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060429885 CMS
AbbVie Inc. $12.3110/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548483 CMS
Amneal Pharmaceuticals LLC $17.7810/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053485647 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $26.6710/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038264941 CMS
AbbVie Inc. $13.8310/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548479 CMS
ANI Pharmaceuticals, Inc. $34.6210/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034105467 CMS
Otsuka America Pharmaceutical, Inc. $24.7109/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014291841 CMS
Genentech USA, Inc. $27.9009/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040409695 CMS
Biogen, Inc. $28.0709/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012202515 CMS
Alexion Pharmaceuticals, Inc. $15.4209/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017076327 CMS
PFIZER INC. $18.0509/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049327662 CMS
Boston Scientific Corporation $22.8709/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022454539 CMS
Eisai Inc. $28.3809/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023316163 CMS
AbbVie Inc. $28.5109/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548475 CMS
Lundbeck LLC $24.9609/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032201669 CMS
Octapharma USA, Inc. $15.2509/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042720163 CMS
ACADIA Pharmaceuticals Inc $21.3209/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053125123 CMS
SK Life Science, Inc. $23.3209/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054722787 CMS
Teva Pharmaceuticals USA, Inc. $18.9909/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056778973 CMS
AbbVie Inc. $13.5009/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548471 CMS
Horizon Therapeutics plc $21.0408/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986978989 CMS
EMD Serono, Inc. $75.6008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032380677 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $28.5808/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038262675 CMS
Neurocrine Biosciences, Inc. $7.6908/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052221179 CMS
AbbVie Inc. $10.0008/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548467 CMS
Abbott Laboratories $35.2008/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019197191 CMS
Biogen, Inc. $24.3208/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012183363 CMS
Neurocrine Biosciences, Inc. $18.5808/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052221175 CMS
Biogen, Inc. $9.4308/28/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012240615 CMS
UCB, Inc. $40.9208/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021421169 CMS
UCB, Inc. $47.8608/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021421209 CMS
AbbVie Inc. $11.6208/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548463 CMS
Acorda Therapeutics, Inc $22.0408/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1005344581 CMS
UCB, Inc. $7.4108/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021421111 CMS
UCB, Inc. $20.9608/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021421125 CMS
Otsuka America Pharmaceutical, Inc. $29.6308/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014291833 CMS
AbbVie Inc. $19.0008/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548459 CMS
ARGENX US, INC. $17.7608/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060429861 CMS
PFIZER INC. $27.9808/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050505451 CMS
AbbVie Inc. $22.8308/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548455 CMS
AbbVie Inc. $29.2508/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548451 CMS
SK Life Science, Inc. $28.3708/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054722731 CMS
Teva Pharmaceuticals USA, Inc. $109.8508/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056778955 CMS
Alexion Pharmaceuticals, Inc. $16.5607/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017086809 CMS
Biogen, Inc. $26.5507/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012261817 CMS
Otsuka America Pharmaceutical, Inc. $27.3507/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014291827 CMS
Novartis Pharmaceuticals Corporation $17.4207/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991761071 CMS
AbbVie Inc. $8.0007/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996548447 CMS
EMD Serono, Inc. $23.3607/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032308955 CMS
IDORSIA PHARMACEUTICALS US INC $23.4307/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034372157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $314.71 6
PY2020 $207.71 19
PY2021 $351.61 5
PY2022 $4,340.47 87
PY2023 $6,947.12 204
PY2024 $4,503.69 203
PY2025 $29,459.97 219

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $589,119.63 54
PY2024 Principal investigator $357,498.46 96
PY2023 Principal investigator $3,737.82 1
PY2022 Principal investigator $3,078.00 1
PY2020 Principal investigator $999.00 1
PY2019 Principal investigator $8,407.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $995.80 12/24/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295383
Principal investigator 1 Ipsen Innovation $1,038.70 12/24/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295385
Principal investigator 1 Ipsen Innovation $995.80 12/24/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295387
Principal investigator 1 Eli Lilly and Company $8.40 12/15/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187893896
Principal investigator 1 Ipsen Innovation $90.00 12/15/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295389
Principal investigator 1 Novartis Pharmaceuticals Corporation $328.78 10/28/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS) No dispute reported 06/30/2026 1190311607
Principal investigator 1 Eli Lilly and Company $1,525.97 10/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187893150
Principal investigator 1 Ipsen Innovation $2,751.59 10/27/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295377
Principal investigator 1 Ipsen Innovation $78.00 10/27/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295379
Principal investigator 1 Ipsen Innovation $2,174.12 10/27/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295381
Principal investigator 1 Eli Lilly and Company $1,416.78 10/08/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893686
Principal investigator 1 Ipsen Innovation $150.00 09/29/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295375
Principal investigator 1 Ipsen Innovation $50.00 09/17/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295373
Principal investigator 1 Ipsen Innovation $995.80 08/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295369
Principal investigator 1 Ipsen Innovation $50.00 08/22/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295371
Principal investigator 1 Ipsen Innovation $150.00 07/29/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295361
Principal investigator 1 Eli Lilly and Company $884.62 07/28/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892930
Principal investigator 1 Ipsen Innovation $995.80 07/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295357
Principal investigator 1 Ipsen Innovation $78.00 07/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295363
Principal investigator 1 Ipsen Innovation $1,038.70 07/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295367
Principal investigator 1 Ipsen Innovation $450.00 07/25/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295359
Principal investigator 1 Ipsen Innovation $100.00 07/17/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295355
Principal investigator 1 Ipsen Innovation $50.00 07/17/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295365
Principal investigator 1 Ipsen Innovation $1,728.22 06/30/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295335
Principal investigator 1 Ipsen Innovation $78.00 06/30/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295337
Principal investigator 1 Ipsen Innovation $1,728.22 06/30/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295339
Principal investigator 1 Ipsen Innovation $2,174.12 06/30/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295341
Principal investigator 1 Ipsen Innovation $78.00 06/30/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295343
Principal investigator 1 Ipsen Innovation $2,751.59 06/30/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295347
Principal investigator 1 Ipsen Innovation $270.00 06/12/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295349
Principal investigator 1 Ipsen Innovation $450.00 06/12/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295351
Principal investigator 1 Ipsen Innovation $300.00 06/12/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295353
Principal investigator 1 Ipsen Innovation $2,000.00 06/11/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295345
Principal investigator 1 Ipsen Innovation $450.00 04/29/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295313
Principal investigator 1 Ipsen Innovation $270.00 04/29/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295315
Principal investigator 1 Ipsen Innovation $995.80 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295309
Principal investigator 1 Ipsen Innovation $1,728.22 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295311
Principal investigator 1 Ipsen Innovation $995.80 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295319
Principal investigator 1 Ipsen Innovation $78.00 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295321
Principal investigator 1 Ipsen Innovation $1,728.22 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295323
Principal investigator 1 Ipsen Innovation $78.00 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295325
Principal investigator 1 Ipsen Innovation $995.80 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295327
Principal investigator 1 Ipsen Innovation $1,729.52 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295329
Principal investigator 1 Ipsen Innovation $995.80 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295331
Principal investigator 1 Ipsen Innovation $995.80 04/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295333
Principal investigator 1 Ipsen Innovation $481.54 04/17/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295317
Principal investigator 1 Eli Lilly and Company $11,320.00 04/01/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187892934
Principal investigator 1 Ipsen Innovation $1,729.52 01/31/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295305
Principal investigator 1 Ipsen Innovation $995.80 01/31/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295307
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $7,936.00 01/28/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK - AVENTURA
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy No dispute reported 06/30/2026 1214124976
Principal investigator 1 Ipsen Innovation $995.80 01/27/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295303
Principal investigator 1 Eli Lilly and Company $243,922.00 01/07/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187891946
Principal investigator 1 Eli Lilly and Company $184,940.00 01/07/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187892736
Principal investigator 1 Eli Lilly and Company $97,803.00 01/07/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892924